Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Medscape Oncology’s Large Presence at ASH 2023

Medscape Education is returning to the annual ASH conference with eight symposia, two publications, and the opportunity for clinicians to challenge their knowledge with MedChallenge.The eight symposia will be held...

Medscape Education

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Impetus Digital

- PMLiVE

Study identifies new amyloid-forming protein linked to early-onset dementia

The TAF15 protein is a new potential therapeutic for frontotemporal dementia

- PMLiVE

Roche shares positive late-stage results for inavolisib combination in advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

AbbVie to expand neuroscience pipeline with $8.7bn Cerevel Therapeutics acquisition

The deal includes a candidate currently in phase 3 testing as a treatment for Parkinson’s disease

- PMLiVE

New terms for UK medicines scheme send ‘mixed message’ to life sciences industry

Life sciences leaders have previously warned against changes to the statutory scheme

- PMLiVE

Medscape Education Redefines Standards with Website Redesign

Medscape Education—the number 1 destination for CME—--has launched a redesign of its education hub. The site now features easy-to-navigate categories, a highlight on curricula, and enhanced search capabilities, allowing Medscape...

Medscape Education

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m

The candidate is currently in late-stage development for tenosynovial giant cell tumour

- PMLiVE

Novartis’ Fabhalta approved by FDA as first oral monotherapy for rare blood disease PNH

The rare blood disease is estimated to affect only ten to 20 people per million worldwide

- PMLiVE

Almirall, BSC and Nostrum Biodiscovery partner for dermatological diseases

The collaboration will aim to find new therapies for dermatological diseases through AI

- PMLiVE

LifeArc launches £5m motor neurone disease drug repurposing programme

Research teams will be eligible to receive up to £750,000 per project through the programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links